Connect with us

Health

Research Shows Interorganisational Deals Boost Drug Discovery, Innovation

Published

on

interorganisational deal

By Adedapo Adesanya

In a recent study published in the journal Drug Discovery Today, a team of scientists at Ritsumeikan University in Japan analysed the changing trends in pharmaceutical industries to spotlight the role of interorganisational collaborations in promoting drug discovery and innovation.

Discovering new drugs has become increasingly rare for independent large pharmaceutical companies in recent times. With numbers showing that almost 60 per cent of new drugs are discovered through mergers and acquisitions and drug licensing.

Now, the university researchers shed light on the recent trends of spinouts from academia and investments in the US and Europe, foreshadowing a promising shift in the industry’s interorganisational deal networks to improve research and development productivity in the future.

“It is a challenging feat to launch a new drug in the market, given the low probability of success during the research and development (R&D) phase and the high costs involved. In recent times, industry trends in external innovation for drug discovery are rapidly changing.  With an improved understanding of disease biology, decision-making can be more streamlined through the effective use of scientific information,” a statement made available to Business Post said.

Led by Associate Professor Kota Kodama of Ritsumeikan University, the team is uncovering how the trends in interorganisational deals in the pharmaceutical industry are changing to improve R&D productivity and drug discovery.

“The network structure of innovation creation in the pharmaceutical industry has changed with the increasing emergence of start-up companies spinning out from academia and research institutions as players in the source of innovation,” explains Dr Kodama, while discussing their investigations into these changing trends and the results of which were made available online on December 27, 2022, and published in volume 28 issue 3 of the journal Drug Discovery Today on March 1, 2023.

Their research suggests that the knowledge necessary for breakthrough innovation in drug discovery is more often than not obtained through alliance networks.

Over the past decade, large research-based pharmaceutical companies have used research collaborations, innovation incubators, academic centres of excellence, public-private partnerships, mergers and acquisitions (M&As), drug licensing, and corporate venture capital funds as typical methods for external innovation.

The researchers now aim to define the changes in the network structure and nature of such alliances that have occurred over the past decade to provide future strategic insights for industry and academic players involved in drug discovery.

Using data from the Cortellis Competitive Intelligence database, the researchers identified nearly 50,000 deals of various kinds related to pharmaceutical R&D across pharmaceutical, digital health software, animal drug, and medical device companies to uncover trends in the creation of new drugs for human use.

They also studied the trends of 13 of the largest pharmaceutical companies with annual revenues of more than $10 billion, who saw an improvement in their CAGR (compound annual growth rate) since 2015.

The researchers noticed that the rising CAGR correlated to a significant change in M&A-related deals after 2015, indicating that M&A-related deals drive revenue growth for large pharmaceutical companies.

Furthermore, the number of organizations involved in interorganisational deals has been increasing yearly from 2012 to 2021. Although the number of organizations involved and the number of deals may be increasing, the density of the deal networks is decreasing annually, suggesting that networks are becoming more non-cohesive.

The concentration of business relationships between organizations of certain areas in the network changed to dispersion around 2015, and new networks connecting different groups started to form after 2017.

These trends are an important illustration of how the industry landscape is gradually evolving away from the traditional network in which large pharmaceutical companies drove drug discovery output. Now, interorganisational deals among more diverse players have become active and are driving R&D productivity for startups in biotechnology and pharmaceuticals.

A clear increase in the number of academia-owned spinouts of advanced technology and expansion of investment in start-ups is a positive sign. The emergence of new chemical modalities, such as biologics, oligonucleotides, and peptides that differ from traditional small molecule drug discovery, indicate remarkable changes that have taken place over the past two decades.

The trend of increased financing for start-up companies in personalized drug development is beneficial for patent creation and will positively impact innovation creation in the coming years.

“The presence of academia to support the technologies of these start-ups is becoming very important, and government and private support and investment in this area are boosting innovation. Our study shows that such medium- and long-term support may ultimately benefit the health and well-being of humankind,” Dr Kodama noted.

interorganisational deal

Adedapo Adesanya is a journalist, polymath, and connoisseur of everything art. When he is not writing, he has his nose buried in one of the many books or articles he has bookmarked or simply listening to good music with a bottle of beer or wine. He supports the greatest club in the world, Manchester United F.C.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Nigeria Launch €4.2m Initiative to Boost Capacity Against Outbreaks

Published

on

health financing fg

By Adedapo Adesanya

Nigeria has launched a €4.2 million programme supported by the European Union (EU) and implemented by the World Health Organisation (WHO) to strengthen the country’s capacity to detect and respond to disease outbreaks.

The initiative, known as the EU Support to Public Health Institutes in Nigeria (EU SPIN), will be carried out over four years in partnership with the Federal Ministry of Health and Social Welfare.

It is aimed at improving the performance of selected public health institutions through better coordination, faster information sharing and enhanced workforce capacity.

Speaking at the launch in Abuja on Monday, the Minister of State for Health and Social Welfare, Mr Iziaq Adekunle Salako, described the programme as a significant step towards strengthening Nigeria’s healthcare system.

“This initiative is designed to strengthen our health institutions, and it is truly a welcome development. It will improve the well-being of Nigerians, especially our vulnerable populations,” he said, noting that it aligns with the federal government’s broader health reform agenda.

Nigeria continues to face a dual health burden, with recurring infectious disease outbreaks alongside a growing prevalence of non-communicable diseases such as hypertension and diabetes.

According to the WHO, non-communicable diseases now account for 27 per cent of deaths in the country, while malaria alone contributes about 30 per cent of global malaria fatalities.

Recurrent outbreaks of cholera, diphtheria, Lassa fever, meningitis and Mpox also remain a major public health concern.

The EU SPIN programme is expected to address systemic gaps that slow outbreak response by strengthening collaboration among public health institutions and clarifying roles across federal, state and local levels.

It will also support real-time data systems to enable quicker and more informed decision-making during health emergencies.

A key component of the initiative is workforce development, with plans to train up to 75 per cent of public health staff in leadership, prevention and response strategies, as well as digital skills.

The European Union Ambassador to Nigeria, Mr Gautier Mignon, said the programme reflects a shared commitment to building resilient health systems.

“Through EU SPIN, the European Union is investing in strong, digitally enabled public health institutions in Nigeria. This partnership underscores our commitment to health security and sustainable systems strengthening,” he said.

Also speaking, the WHO Representative in Nigeria, Mr Pavel Ursu, noted that improved coordination and digital tools would enhance the country’s ability to protect lives.

“By improving coordination, skills and digital tools, the project will help protect lives and keep communities healthier,” he said.

Officials said the programme would ultimately strengthen links between public health systems and primary healthcare services, ensuring that communities benefit from faster and more effective responses to health threats.

By 2028, the initiative is expected to deliver more efficient inter-agency coordination, clearer institutional responsibilities and more reliable public health data nationwide, with progress tracked through national monitoring systems and periodic reviews involving government and development partners.

Continue Reading

Health

Malaria: SUNU Health Advocates Wider Adoption of HMO Plans

Published

on

SUNU Health --logo

By Aduragbemi Omiyale

To achieve a malaria-free Nigeria, a leading Health Maintenance Organisation (HMO) with a robust nationwide presence, SUNU Health Nigeria Limited, has called for a wider adoption of HMO packages for citizens.

It stressed that managed care provides a critical safety net, ensuring families can access quality preventive services without the burden of immediate, high costs, adding that this structured approach transforms healthcare from an unpredictable expense into a manageable, guaranteed service.

The company, which officially unveiled a comprehensive strategic roadmap aimed at drastically cutting down on malaria-related deaths, emphasised that the disease can be eradicated if citizens and stakeholders adopt consistent preventive measures.

“Eradication is within our reach if we synchronise our efforts,” the chief operating officer of SUNU Health, Dr Faith Nwachi, said, noting that the tools for victory range from environmental hygiene to the consistent use of treated nets, which are easily accessible to every Nigerian.

The organisation noted that it came up with the latest framework to significantly reduce the disease burden that has historically hindered Nigeria’s productivity and public health stability.

The urgency of this intervention is underscored by concerning data from late 2025, which revealed a sharp upward trend in cases, it stated.

With over 24.5 million confirmed cases reported in the first nine months of last year alone, the 2026 landscape demands aggressive action. Currently, malaria remains a leading cause of mortality, responsible for approximately 30 per cent of child deaths and 11 per cent of maternal deaths annually.

A central pillar of the roadmap is a focus on preventative care. As of early 2026, according to the World Health Organisation, malaria still accounts for nearly 30 per cent of all hospital admissions in Nigeria.

By addressing the root causes and transmission cycles, SUNU Health seeks to drastically lower these statistics, ensuring Nigerians can lead more active lives without the constant threat of infection.

Dr Nwachi further underscored the economic necessity of this shift, stating that “prevention is significantly cheaper than cure.”

The financial toll on the Nigerian economy is staggering, with billions of Naira lost annually to treatments and diminished man-hours. For the average family, frequent bouts of illness lead to catastrophic out-of-pocket expenses that undermine financial security.

Continue Reading

Health

AltBank, Partners Recommend Autism Care Financing Options, Others to Government

Published

on

Autism Care Financing Options

By Aduragbemi Omiyale

Plans are underway by the Alternative Bank (AltBank) to present a policy brief to relevant government ministries, recommending vocational pathways, autism care financing options, and a 12-month Lagos pilot across selected schools and primary healthcare centres.

The recommendations are from the inaugural Autism Stakeholders Roundtable and Policy Dialogue in Lagos, organised by the lender in partnership with the Private Sector Health Alliance of Nigeria (PSHAN), Eliakim Foundation, and Sterling One Foundation under the theme, It is How You Show Up.

The programme served as a critical platform to address the country’s fragmented autism support systems, with leading healthcare professionals, policymakers, and autism advocates in attendance, praising the financial institution’s decisive shift toward early intervention, systemic inclusion, and comprehensive capacity building for parents and caregivers.

The president of the Medical Women’s Association of Nigeria (MWAN) Lagos State Branch, Dr Ime Okon, stressed her group’s alignment with the bank’s initiatives.

“We recognise caregivers and families as central to the success of any intervention. We are showing up, holding their hands, to ensure they are never left to navigate this journey alone.

“For a physician, showing up means ensuring that a parent’s first concern is met with a strengthened, inclusive system rather than a clinical dead-end with no solution. The Alternative Bank has signalled a shift toward a high-level platform for national action,” she stated.

Validating this urgent need for systemic early response, the keynote speaker and founder of the Patrick Speech and Languages Centre (PSLC), Mrs Dotun Akande, advocated the integration of universal developmental screening into primary healthcare, stressing that Nigeria must transition from relying on parallel private centres to building a coordinated national response.

“What Nigeria must now build is a system where intervention happens early, equitably, and at scale, without depending on chance, geography, or privilege,” Mrs Akande noted, outlining the necessity of a caregiver support scheme that addresses both the financial and social needs of families navigating autism.

Answering this call to action, the Executive Director of Commercial and Institutional Banking (Lagos and Southwest) at The Alternative Bank, Mrs Korede Demola-Adeniyi, unveiled the financial institution’s concrete commitments to parent and professional training.

Noting that showing up in Nigeria has “too often meant showing up late,” she announced a robust three-pillar intervention agenda focusing on inclusive education, targeted training for caregivers and health professionals, and behavioural change advocacy.

As an immediate first step, Mrs Demola-Adeniyi announced the launch of a specialised capacity-building programme on Receptive Language Disorder, executed in collaboration with Eliakim Global Resources, which commenced on Sunday, April 26, 2026.

“Early recognition and sustained support depend on a workforce and caregivers who know what to look for, and what to do next,” she explained, emphasising that receptive language is a consequential developmental marker that is frequently missed.

The roundtable fostered dynamic discussions on practically designing and sustainably funding high-impact support programmes.

Continue Reading

Trending